Abu Dhabi Public Health Centre and Novartis Middle East Sign MoU to Enhance Public Health Awareness and Disease Prevention in Abu Dhabi

The ABU Dhabi Public Health Center (ADPHC) has signed a memorandum of understanding (MOU) with Novartis Middle East Fze (Novartis), an innovative company of medicine, to create awareness, early prevention, participable and improve the practices of desires, chronic disease of Abu Dhabi Demonaviravaravaravaravaravaravaravaravaravaravaravaravaravaravaravinables.

The Mou was signed by him Rashed Obaid Asawaidi – General Director, which represents ADPHC, and Mohamed Ezz Eldin, head of GCC, who represents Novartis, on May 13, the 25th Iuhpe World Conference on Health Promot Tahake, Tahake, Tahoke. Exhibition center (ADNEC).

Dr. Rashed Obaid Alsuwaidi-Director General of ADPHC said: “This memorandum of understanding is a vital step in our trip to public health systems of strengths and reduces the impact of noncommunicable diseases in Abu Dhabi. We point to long-term strategic collaborations.”

Mohamed Ezz Eldin, Head of GCC at Novartis Said: “We are proud to partner with the abu dhabi public health center in a mission that aligns with our commitment to advancing patient care. Disease Management.

According to the two-year agreement, ADPHC and Novartis will collaborate to create and execute awareness campaigns through digital and traditional channels, increasing public awareness about risk factors, early symptoms and the importance of regularity for non-communication-communicae.

The collaboration is built around three strategic pillars:

• Disease awareness: Development of shocking campaigns to increase public awareness and educate communities about noncommunicable diseases such as cardiovascular conditions, diabetes and chronic renal disease. These initiatives will take advantage of online and offline channels to promote proactive health behaviors such as routine tests.
• Disease prevention: Design and implementation of effective initiatives focused on primary prevention of adult cardiovascular diseases, diabetes and chronic renal disease. Activities include specific detection efforts to identify people at early risk.
• Best practices shared in disease management: Collaboration to identify, share and implement best practices throughout the patient’s trip. This includes early detection protocols, preventive strategies and disease management models, taking advantage of the global experience of AMD practices to improve patient results and improve health system performance.

The MOU also establishes a dedicated work group, and each party designates an advantage to coordinated efforts. The working group will gather regularly to align in the project plans, evaluate the viability, define key deliverables and results evaluated through key performance indicators (KPI) in accordance. The KPI will be reviewed biannual to guarantee alignment with strategic objectives and to adapt to emerging public health needs.